Patel Bhavesh M, Chittock Dean R, Russell James A, Walley Keith R
Department of Critical Care, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Anesthesiology. 2002 Mar;96(3):576-82. doi: 10.1097/00000542-200203000-00011.
Septic shock is associated with vasopressin deficiency and a hypersensitivity to its exogenous administration. The goal of the current study was to determine whether short-term vasopressin infusion in patients experiencing severe septic shock has a vasopressor sparing effect while maintaining hemodynamic stability and adequate end-organ perfusion.
Patients experiencing septic shock that required high-dose vasopressor support were randomized to a double-blinded 4-h infusion of either norepinephrine (n = 11) or vasopressin (n = 13), and open-label vasopressors were titrated to maintain blood pressure. To assess end-organ perfusion, urine output and creatinine clearance, gastric mucosal carbon dioxide tension, and electrocardiogram ST segment position were measured.
Patients randomized to norepinephrine went from a median prestudy norepinephrine infusion of 20.0 microg/min to a blinded infusion of 17.0 mug/min at 4 h, whereas those randomized to vasopressin went from a median prestudy norepinephrine infusion of 25.0 microg/min to 5.3 microg/min at 4 h (P < 0.001). Mean arterial pressure and cardiac index were maintained in both groups. Urine output did not change in the norepinephrine group (median, 25 to 15 ml/h) but increased substantially in the vasopressin group (median, 32.5 to 65 ml/h; P < 0.05). Similarly, creatinine clearance did not change in the norepinephrine group but increased by 75% in the vasopressin group (P < 0.05). Gastric mucosal carbon dioxide tension and electrocardiogram ST segments did not change significantly in either group.
The authors conclude that short-term vasopressin infusion spared conventional vasopressor use and improved some measures of renal function in patients with severe septic shock.
感染性休克与血管加压素缺乏以及对外源性血管加压素给药的超敏反应有关。本研究的目的是确定在严重感染性休克患者中短期输注血管加压素是否具有血管升压药节省作用,同时维持血流动力学稳定性和足够的终末器官灌注。
需要高剂量血管升压药支持的感染性休克患者被随机分为两组,分别接受4小时的去甲肾上腺素双盲输注(n = 11)或血管加压素输注(n = 13),开放标签的血管升压药进行滴定以维持血压。为评估终末器官灌注,测量尿量、肌酐清除率、胃黏膜二氧化碳张力和心电图ST段位置。
随机分配至去甲肾上腺素组的患者,研究前去甲肾上腺素输注中位数为20.0μg/min,4小时时双盲输注为17.0μg/min;而随机分配至血管加压素组的患者,研究前去甲肾上腺素输注中位数为25.0μg/min,4小时时降至5.3μg/min(P < 0.001)。两组均维持平均动脉压和心脏指数。去甲肾上腺素组尿量未改变(中位数,25至15ml/h),而血管加压素组尿量显著增加(中位数,32.5至65ml/h;P < 0.05)。同样,去甲肾上腺素组肌酐清除率未改变,而血管加压素组肌酐清除率增加了75%(P < 0.05)。两组胃黏膜二氧化碳张力和心电图ST段均无显著变化。
作者得出结论,短期输注血管加压素可减少传统血管升压药的使用,并改善严重感染性休克患者的一些肾功能指标。